NCT03576651已完成1 期
A Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
JHL Biotech, Inc.2 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2018年3月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 154
- 试验地点
- 2
- 主要终点
- AUC0-inf
研究概览
简要总结
This is a Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) Sourced from the European Union (EU) and the Union States (US) in Healthy Male Volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers,
- •Age range of 21-55 years (inclusive).
- •BMI range of 18.0-30.0 kg/m2 (inclusive) and a total body weight >50 kg.
- •Medically healthy subjects with normal organ functions and laboratory values
- •Subjects must be willing to use adequate contraception and not donate sperm from admission to clinical research center until 6 months post dosing.
- •All intermittent medications including over the counter, herbal and nutriceuticals, must be stopped at least 14 days prior to admission to the clinical research center.
- •Ability and willingness to abstain from alcohol 48hrs prior to admission to the clinical research center, and throughout the dosing and evaluation period.
- •No significant medical history per the PI judgment.
- •ECGs (via 12 lead) showing normalized cumulative sum (NCS) findings per PI judgment
- •Ability to provide informed consent for the study.
排除标准
- •Previous treatment with an anti-vascular endothelial growth factor (VEGF) antibody or any other antibody or protein targeting the VEGF receptor or treatment with an immunobiological drug during the last three months.
- •Previous history of cancer other than adequately treated basal cell or squamous cell carcinoma of the skin.
- •Received blood transfusions and blood donation within 3 months before screening date.
- •Resting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg.
- •Any other severe physical incapacity.
- •Positive serological test for hepatitis B surface antigen or positive antibody for hepatitis C virus or positive antibody for human immunodeficiency virus (type 1 and 2).
- •Tuberculosis (TB) or an acute systemic infection; demonstrated by positive QuantiFERON-TB and/or Chest radiograph conducted up to 3 months prior or during the screening visit.
- •Major surgery planned for the study duration or cases with major surgery in the past 28 days before screening.
- •History of relevant drug and/or food related allergies.
- •History of or known hypersensitivity to bevacizumab or other recombinant human or humanized antibodies or inactive ingredients.
- •History of alcohol and or drug abuse/addiction.
- •Positive alcohol breath test and drug screen for opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines.
- •Strenuous exercise 96 hrs prior to admission to the clinical research center.
- •Any significant or acute illness within 30 days prior to the expected first dose of study drug.
- •Unsuitable veins for infusion and/or venepuncture.
- •History of bleeding disorders, thromboembolic conditions, gastrointestinal perforations or any fistulae, orthostatic hypotension, fainting spells, blackouts for any reasons; as well as presence of a non-healing wound or fracture.
- •Participation in another clinical study where the investigational drug was received within < 5 x half-lives of the drug (120 days prior to screening).
- •Any condition or displayed behaviour that the investigator in their best clinical judgement believes could be detrimental the subject's participation in the study or result in unfavourable outcomes for the subject or study (eg. Clear signs that the patient is withholding information on their substance use/abuse status).
结局指标
主要结局
AUC0-inf
时间窗: up to 71 days
area under the concentration-time curve from time zero to infinity (AUC0-inf)
次要结局
- AUClast(up to 71 days)
- Cmax(up to 71 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy SubjectsHealthyNCT03970824Celltrion312
已完成
1 期
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy SubjectsPsoriasisNCT04711343Bio-Thera Solutions216
已完成
1 期
Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy SubjectsPsoriasisNCT04371185Bio-Thera Solutions270
已完成
1 期
Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy SubjectsRheumatoid ArthritisNCT03606876Bio-Thera Solutions138
已完成
1 期
To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed AvastinHealthyNCT03247673Celltrion141